These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29546476)

  • 1. Ceramide stearic to palmitic acid ratio predicts incident diabetes.
    Hilvo M; Salonurmi T; Havulinna AS; Kauhanen D; Pedersen ER; Tell GS; Meyer K; Teeriniemi AM; Laatikainen T; Jousilahti P; Savolainen MJ; Nygård O; Salomaa V; Laaksonen R
    Diabetologia; 2018 Jun; 61(6):1424-1434. PubMed ID: 29546476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between ceramides and coronary artery stenosis in patients with coronary artery disease.
    Tu C; Xie L; Wang Z; Zhang L; Wu H; Ni W; Li C; Li L; Zeng Y
    Lipids Health Dis; 2020 Jun; 19(1):151. PubMed ID: 32586390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort.
    Havulinna AS; Sysi-Aho M; Hilvo M; Kauhanen D; Hurme R; Ekroos K; Salomaa V; Laaksonen R
    Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2424-2430. PubMed ID: 27765765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography.
    Mantovani A; Bonapace S; Lunardi G; Canali G; Dugo C; Vinco G; Calabria S; Barbieri E; Laaksonen R; Bonnet F; Byrne CD; Targher G
    Diabetes Metab; 2020 Apr; 46(2):150-157. PubMed ID: 31386900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.
    Laaksonen R; Ekroos K; Sysi-Aho M; Hilvo M; Vihervaara T; Kauhanen D; Suoniemi M; Hurme R; März W; Scharnagl H; Stojakovic T; Vlachopoulou E; Lokki ML; Nieminen MS; Klingenberg R; Matter CM; Hornemann T; Jüni P; Rodondi N; Räber L; Windecker S; Gencer B; Pedersen ER; Tell GS; Nygård O; Mach F; Sinisalo J; Lüscher TF
    Eur Heart J; 2016 Jul; 37(25):1967-76. PubMed ID: 27125947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy.
    Mantovani A; Bonapace S; Lunardi G; Salgarello M; Dugo C; Canali G; Byrne CD; Gori S; Barbieri E; Targher G
    Metabolism; 2018 Aug; 85():305-312. PubMed ID: 29777715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus.
    Cao R; Fang Z; Li S; Xu M; Zhang J; Han D; Hu W; Yan L; Wang Y; Fan L; Cao F
    Front Physiol; 2020; 11():1104. PubMed ID: 33041846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes.
    Mantovani A; Altomari A; Lunardi G; Bonapace S; Lippi G; Bonnet F; Targher G
    Diabetes Metab; 2020 Sep; 46(4):326-330. PubMed ID: 31185304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes.
    Wretlind A; Curovic VR; Suvitaival T; Theilade S; Tofte N; Winther SA; Vilsbøll T; Vestergaard H; Rossing P; Legido-Quigley C
    Diabetes; 2023 Oct; 72(10):1493-1501. PubMed ID: 37478203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceramide d18:1/24:1 as a potential biomarker to differentiate obesity subtypes with unfavorable health outcomes.
    Yu B; Hu M; Jiang W; Ma Y; Ye J; Wu Q; Guo W; Sun Y; Zhou M; Xu Y; Wu Z; Wang Y; Lam SM; Shui G; Gu J; Li JZ; Fu Z; Gong Y; Zhou H
    Lipids Health Dis; 2023 Oct; 22(1):166. PubMed ID: 37794463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease.
    Mantovani A; Lunardi G; Bonapace S; Dugo C; Altomari A; Molon G; Conti A; Bovo C; Laaksonen R; Byrne CD; Bonnet F; Targher G
    Diabetes Metab; 2021 Feb; 47(1):101152. PubMed ID: 32283179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal obesity leads to long-term altered levels of plasma ceramides in the offspring as revealed by a longitudinal lipidomic study in children.
    León-Aguilar LF; Croyal M; Ferchaud-Roucher V; Huang F; Marchat LA; Barraza-Villarreal A; Romieu I; Ramakrishnan U; Krempf M; Ouguerram K; Mercado-Camargo R; Bolaños-Jiménez F
    Int J Obes (Lond); 2019 Jun; 43(6):1231-1243. PubMed ID: 30568270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Higher Circulating Leucine-Rich α-2 Glycoprotein 1 Concentrations and Specific Plasma Ceramides in Postmenopausal Women with Type 2 Diabetes.
    Mantovani A; Csermely A; Sani E; Beatrice G; Petracca G; Lunardi G; Bonapace S; Lippi G; Targher G
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceramide ratios are affected by cigarette smoke but not heat-not-burn or e-vapor aerosols across four independent mouse studies.
    Lavrynenko O; Titz B; Dijon S; Santos DD; Nury C; Schneider T; Guedj E; Szostak J; Kondylis A; Phillips B; Ekroos K; Martin F; Peitsch MC; Hoeng J; Ivanov NV
    Life Sci; 2020 Dec; 263():118753. PubMed ID: 33189821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI-HF trial.
    Targher G; Lunardi G; Mantovani A; Meessen J; Bonapace S; Temporelli PL; Nicolis E; Novelli D; Conti A; Tavazzi L; Maggioni AP; Latini R
    ESC Heart Fail; 2020 Dec; 7(6):3288-3297. PubMed ID: 32627354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Ceramides and Cardiovascular Events in Hypertensive Patients at High Cardiovascular Risk.
    Yin W; Li F; Tan X; Wang H; Jiang W; Wang X; Li S; Zhang Y; Han Q; Wang Y; Du J
    Am J Hypertens; 2021 Nov; 34(11):1209-1216. PubMed ID: 34232291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma ceramides are associated with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction.
    Pan W; Li L; Sun M; Wang C; Fang S; Yu B
    Int J Cardiol; 2020 Dec; 320():155-160. PubMed ID: 32800902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.
    Hilvo M; Meikle PJ; Pedersen ER; Tell GS; Dhar I; Brenner H; Schöttker B; Lääperi M; Kauhanen D; Koistinen KM; Jylhä A; Huynh K; Mellett NA; Tonkin AM; Sullivan DR; Simes J; Nestel P; Koenig W; Rothenbacher D; Nygård O; Laaksonen R
    Eur Heart J; 2020 Jan; 41(3):371-380. PubMed ID: 31209498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long- and very long-chain ceramides are predictors of acute kidney injury in patients with acute coronary syndrome: the PEACP study.
    Liang L; Li D; Zeng R; Zhang H; Lv L; Wei W; Wan Z
    Cardiovasc Diabetol; 2023 Apr; 22(1):92. PubMed ID: 37081501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between elevated plasma ceramides and plaque rupture in patients with ST-segment elevation myocardial infarction.
    Pan W; Sun M; Wu J; Dong H; Liu J; Gao R; Fang S; Xing L; Hu S; Yu B
    Atherosclerosis; 2020 Jun; 302():8-14. PubMed ID: 32387714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.